Media coverage about Baxter International (NYSE:BAX) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Baxter International earned a news impact score of 0.18 on Accern’s scale. Accern also gave news articles about the medical instruments supplier an impact score of 45.6410189223301 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Here are some of the media stories that may have effected Accern’s rankings:
- Baxter to Post 1Q18 Earnings on April 26: Can It Beat Estimates? (finance.yahoo.com)
- Brisbane Airport’s new international terminal unveiled (9news.com.au)
- [$$] Allied Healthcare lines up rescue plan (finance.yahoo.com)
- Stock’s Liquidity Overview – Baxter International Inc. (NYSE:BAX) (nasdaqjournal.com)
- Global Automatic Pill Dispenser Machine Market 2018 – Baxter International Inc., Becton, Dickinson and Company … (nwctrail.com)
Shares of NYSE:BAX traded down $1.03 during mid-day trading on Tuesday, reaching $66.15. 3,787,546 shares of the company traded hands, compared to its average volume of 3,247,044. The company has a market cap of $36,216.31, a PE ratio of 26.67, a price-to-earnings-growth ratio of 1.83 and a beta of 0.80. The company has a current ratio of 2.57, a quick ratio of 2.05 and a debt-to-equity ratio of 0.38. Baxter International has a 52 week low of $53.04 and a 52 week high of $72.58.
The business also recently disclosed a quarterly dividend, which was paid on Monday, April 2nd. Investors of record on Friday, March 2nd were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, March 1st. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.97%. Baxter International’s dividend payout ratio (DPR) is presently 25.81%.
Baxter International declared that its Board of Directors has initiated a share buyback plan on Tuesday, February 20th that authorizes the company to buyback $1.50 billion in shares. This buyback authorization authorizes the medical instruments supplier to purchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s management believes its stock is undervalued.
BAX has been the subject of a number of recent analyst reports. Zacks Investment Research lowered Baxter International from a “buy” rating to a “hold” rating in a research report on Tuesday, December 26th. JPMorgan Chase raised shares of Baxter International from a “neutral” rating to an “overweight” rating in a research report on Tuesday, January 2nd. Bank of America raised shares of Baxter International from a “neutral” rating to a “buy” rating in a research report on Tuesday, January 2nd. Evercore ISI started coverage on shares of Baxter International in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $71.00 price target for the company. Finally, Raymond James raised shares of Baxter International from a “market perform” rating to an “outperform” rating and set a $73.00 price target for the company in a research report on Wednesday, January 3rd. Six analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. Baxter International currently has a consensus rating of “Buy” and an average target price of $71.13.
In related news, Director Peter S. Hellman sold 3,760 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $64.74, for a total transaction of $243,422.40. Following the completion of the transaction, the director now directly owns 25,522 shares in the company, valued at approximately $1,652,294.28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director James R. Gavin III sold 18,750 shares of the business’s stock in a transaction that occurred on Wednesday, March 28th. The shares were sold at an average price of $64.56, for a total value of $1,210,500.00. Following the transaction, the director now owns 36,398 shares of the company’s stock, valued at $2,349,854.88. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 27,500 shares of company stock valued at $1,783,512. 0.07% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Baxter International (BAX) Receiving Somewhat Positive Press Coverage, Report Finds” was first published by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3385801/baxter-international-bax-receiving-somewhat-positive-press-coverage-report-finds.html.
Baxter International Company Profile
Baxter International Inc provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.